Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
暂无分享,去创建一个
Milind B. Suraokar | K. Coombes | B. Garcia | J. Minna | I. Wistuba | L. Girard | A. Gazdar | S. Swisher | R. Kittler | C. Behrens | R. Zhong | Yang Xie | J. Rodriguez-Canales | Yunyun Zhou | M. Suraokar | J. Bayo | N. Bhanu | N. Kalhor | E. Martinez | E. Parra | P. Villalobos | A. Pataer | Maithili P. Dalvi | P. Yenerall | B. Mino | B. Timmons | Lei Wang | J. Heymach | R. Kollipara | Hyunsil Park | Elisabeth D. Martinez
[1] Shawn M. Gillespie,et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.
[2] P. Trojer,et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.
[3] J. O’Leary,et al. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. , 2015, Experimental cell research.
[4] R. Neve,et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. , 2014, Cancer research.
[5] Christopher J. Ott,et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.
[6] Barbara Mair,et al. Exploiting epigenetic vulnerabilities for cancer therapeutics. , 2014, Trends in pharmacological sciences.
[7] S. Peña-Llopis,et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth , 2013, Nature Communications.
[8] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.
[9] Christopher J. Schofield,et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.
[10] Ji-Young Kim,et al. KDM3B Is the H3K9 Demethylase Involved in Transcriptional Activation of lmo2 in Leukemia , 2012, Molecular and Cellular Biology.
[11] G. Almouzni,et al. The double face of the histone variant H3.3 , 2011, Cell Research.
[12] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[13] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Mikkelsen,et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.
[15] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[16] Yang Xie,et al. Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology , 2008, Nucleic acids research.
[17] J. Luketich,et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.
[18] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[19] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[20] P. Pelicci,et al. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53 , 2005, Oncogene.
[21] Diane D. Liu,et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. , 2003, Lung cancer.
[22] M. Kris,et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[24] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[25] R. Arceci,et al. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Lemontt,et al. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. , 1988, Cancer research.
[27] I. Pastan,et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.